Teeratas Kansom

Dr. Teeratas Kansom

orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 December 2019 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
TKTeeratas Kansom
Teeratas Kansom
WSWarayuth Sajomsang
Warayuth Sajomsang
RSRungnapha Saeeng
Rungnapha Saeeng
TRTheerasak Rojanarata
Theerasak Rojanarata
TNTanasait Ngawhirunpat
Tanasait Ngawhirunpat
POPraneet Opanasopit
Praneet Opanasopit

16 August 2018 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
TKTeeratas Kansom
Teeratas Kansom
WSWarayuth Sajomsang
Warayuth Sajomsang
RSRungnapha Saeeng
Rungnapha Saeeng
PCPurin Charoensuksai
Purin Charoensuksai
POPraneet Opanasopit
Praneet Opanasopit
PTPrasopchai Tonglairoum
Prasopchai Tonglairoum

6 April 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
PSPhuvamin Suriyaamporn
Phuvamin Suriyaamporn
TKTeeratas Kansom
Teeratas Kansom
TCThapakorn Charoenying
Thapakorn Charoenying
TNTanasait Ngawhirunpat
Tanasait Ngawhirunpat
TRTheerasak Rojanarata
Theerasak Rojanarata
BPBoonnada Pamornpathomkul
Boonnada Pamornpathomkul

19 December 2024 in Pharmacia
Verified
Journal Article
Open access
DJDareena Jaiseri
Dareena Jaiseri
SPSupusson Pengnam
Supusson Pengnam
POPraneet Opanasopit
Praneet Opanasopit
TNTanasait Ngawhirunpat
Tanasait Ngawhirunpat
TRTheerasak Rojanarata
Theerasak Rojanarata
TCThapakorn Charoenying
Thapakorn Charoenying
Currently, fused deposition modeling (FDM) is a 3D printing technology that has been most widely used to develop innovative drug delivery approaches for overcoming the limitations of oral drug administration. Propranolol has a short plasma half-life and is well soluble in acidic environments. Thus, this study aimed to develop a gastro-floating 3D printed device (GFD) to sustain the release of propranolol in the stomach as a gastro-retentive drug delivery system. The polylactic acid (PLA) was selected to fabricate the GFD. An air chamber was included in the interior construction of the GFD design for buoyancy. The number of open channels on the side wall of GFD was modified to regulate release. The propranolol gel formulation was composed of a mixture of propranolol and polyvinylpyrrolidone (PVP) at the weight ratio of 6:5 and was then loaded into GFDs using a syringe. GFD exhibited a floating ability of more than 24 h with low standard deviation (SD) values of weight variation and shape dimension. The propranolol release from GFD shows sustained release properties in the simulated gastric environment without lag time. The 4 and 5 channels of GFD exhibited sustained drug release for 6 h. In addition, the duration of sustained release for 8 h was achieved from the GFD with 2 and 3 channels. The kinetic release of propranolol from GFDs was the best fit with zero-order. Thus, the GFDs could be designed to control the drug release according to each patient, which has the potential for applying personalized gastro-retentive drug delivery in various medications. Graphical abstract

1 August 2019 in Key Engineering Materials
Verified
Journal Article
Closed access
PDF file
TKTeeratas Kansom
Teeratas Kansom
EDEkachai Dumkliang
Ekachai Dumkliang
PPPrasopchai Patrojanasophon
Prasopchai Patrojanasophon
WSWarayuth Sajomsang
Warayuth Sajomsang
RSRungnapha Saeeng
Rungnapha Saeeng
POPraneet Opanasopit
Praneet Opanasopit
A site-specific drug delivery system of anticancer agents has been delveloped to enhance the therapeutic efficacy and reduce toxicity to the normal tissue. Semi-synthetic andrographolide analogue 3A.1 (19-tert-butyldiphenylsilyl-8,17-epoxy andrographolide) is one of the potential natural anticancer compounds against many types of cancer including colorectal cancer cells. However, the clinical applications of this compound are limited because of low water solubility and lack of suitable delivery carriers. This study aimed to increase the aqueous solubility and improve the anticancer efficacy of 3A.1 via active targeting approaches. In this study, 3A.1 was loaded into the polymeric micelles self-assembled from N-naphthyl-N,O-succinyl chitosan (NSC). The micelles were conjugated with folate moiety (Fol-NSC) for targeting to the cancer cells. All of the 3A.1-loaded micelles were prepared by dropping method, and the physicochemical properties (size, charge, morphology, encapsulating efficiency, loading capacity), in vitro release behavior and in vitro anticancer activities against HT29 colorectal cancer cells were investigated. The 3A.1-loaded micelles were successfully formulated by dropping method using NSC or Fol-NSC. The micelles loaded with 40% initial 3A.1 showed the maximum encapsulating efficiency and loading capacity. The micelles were in the nanometer range, having a negative surface charge and a spherical structure. The colon site-specific release of the 3A.1 from the 3A.1-loaded micelles was obtained. The release of 3A.1 from the Fol-NSC micelles was slower than that from the NSC micelles. Moreover, the Fol-NSC micelles exhibited superior anticancer efficacy than that of the NSC micelles and free 3A.1. In conclusions, the 3A.1-loaded Fol-NSC micelles developed in the present study had suitable physicochemical properties. These nanocarriers may be a potential delivery system for targeted delivery of the 3A.1 to colorectal cancer cells.

9 October 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DJDareena Jaiseri
Dareena Jaiseri
SPSupusson Pengnam
Supusson Pengnam
POPraneet Opanasopit
Praneet Opanasopit
PSPhuvamin Suriyaamporn
Phuvamin Suriyaamporn
CPChaiyakarn Pornpitchanarong
Chaiyakarn Pornpitchanarong
TCThapakorn Charoenying
Thapakorn Charoenying
Background: Isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HDZ) are dual cardiovascular drugs used to treat heart failure. However, the drugs have limitations such as short plasma half-life, low bioavailability, and potential for tolerance of the nitrate component. To address the need for prolonged drug release, a floating dual-compartment drug delivery system was developed to provide controlled drug release under simulated gastric dissolution conditions. Objectives: This study aimed to develop floating dual-compartment devices (FDCDs) to contain ISDN and HDZ gel and modify drug release under simulated gastric conditions. Methods: The FDCD was designed in a cylindrical shape consisting of an air chamber on the upper part for floating ability, and two compartments for loaded drug gel and controlling the drug release rate. Fused deposition modeling (FDM) was selected to fabricate FDCDs using polylactic acid (PLA) filament. The ISDN formulation varied the ratio of polyvinylpyrrolidone (PVP) to achieve drug release for 12 h. The HDZ formulation was optimized by varying the ratio of PVP and hydroxypropyl methylcellulose (HPMC) to extend drug release at 24 h. Results: The shape dimension and weight variation in the FDCDs showed low standard deviation (SD). FDCDs exhibited immediate floating, resisted overturning, and demonstrated in vitro floating ability for more than 24 h. The formulation ISDN3 at a PVP: drug: water ratio of 5:2:3 exhibited complete release at 12 h, while the formulation of HDZ1 at an HPMC: PVP: drug: water ratio of 0.3:2.5:2:5.2 showed complete release within 24 h. The ISDN3- and HDZ1-loaded FDCDs demonstrated prolonged release behavior, with ISDN and HDZ release profiles showing the best fit to the zero-order and Higuchi models, respectively, based primarily on the coefficient of determination (R2), while root mean square error (RMSE) was used as a complementary measure of fitting error. Conclusions: These findings suggest that the developed dual-drug-loaded FDCD has potential as a dual-drug oral delivery platform for simultaneous delivery of ISDN and HDZ with prolonged drug release characteristics and further development of oral combination drug delivery systems.